

# Five Key Reasons to Attend SMI's 21st Annual Pain Therapeutics Conference

*SMi Group Reports Pain Therapeutics Virtual Conference, 10-11 May 2021 is sponsored by Transpharmation and MD Biosciences, announces five key reasons to attend*

LONDON, LONDON, UNITED KINGDOM, February 19, 2021 /EINPresswire.com/ -- Convening on the 10th and 11th of May 2021, SMI Group are delighted to host its [21st Annual Pain Therapeutics Conference](#) which will provide insights into cutting edge drug discovery science, preclinical development trends and will explore novel pain drug targets and novel biomarkers. It will also [explore how COVID-19 has changed](#) the experience of clinical trials and presented an opportunity to reform approach to data verification, analysis, collection and more.

Interested parties can attend the conference at only £299 for pharmaceutical and biotechnology companies and £699 for vendors and commercial firms.

<http://www.pain-therapeutics.co.uk/pr2>

With a [strong programme and an expert speaker line-up](#), SMI Group share the top five key reasons to join the conference:

## 1. AstraZeneca opening address – Clinical Development on Osteoarthritis

Update: Demonstration of significant pain relief in subjects with painful osteoarthritis of the knee with a novel anti NGF, anti-TNFα bispecific fusion protein

Presented by Iain Chessell, Global Head of Neuroscience, BioPharmaceuticals Research & Development from AstraZeneca

## 2. National Institutes of Health Spotlight Session – Expansion of Pain Research

Exploring the expansion of pain research at the National Institutes of Health

Presented by David Thomas, Senior Advisor National Institutes of Health



SMi Group Proudly Presents the 21st Annual conference on

# Pain Therapeutics

Explore cutting edge drug discovery science and key clinical-stage pain therapies in the pipeline

CONFERENCE: 10TH-11TH MAY 2021

VIRTUAL CONFERENCE: ONLINE ACCESS ONLY

**KEY REASONS TO ATTEND THE VIRTUAL CONFERENCE:**

- Discover which innovative new therapies are driving critical development including case studies from Novaramid and Vopagenic
- Examine the best strategies to generate more funding in pain research clinical trials to elevate the level of understanding
- Explore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification, data analysis and data collection
- Understand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy
- Virtual Conference Benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with other attendees, and virtual meetings and networking socials. For full details see p.3

**CHAIRS FOR 2021:**

- Michael Scherz, Founder and CEO, Melys Pharma
- Naheed Mirza, Early Development Pain & CNS Specialist

**FEATURED 2021 SPEAKERS INCLUDE:**

- Iain Chessell, Global Head of Neuroscience, BioPharmaceuticals Research & Development, AstraZeneca
- Mikhail Kalichev, Director, in vivo Neurology, Ipsen
- Dalma Sugar, Director Medical Affairs, Teva Pharmaceuticals
- Achim Klein, Pain Genetics Lead, Eli Lilly
- Jun Chen, Senior Scientist, Genentech
- Richard Millamul, Chief Medical Officer and EVP, Collegium Pharmaceuticals
- Guido Koppmann, Chief Scientific Officer, Allogix Pharmaceuticals
- Randall Kaye, Chief Medical Officer, Neurana Pharmaceuticals
- ...and many more!

SPONSORED BY

Transpharmation  
Science that translates into results

CPD Accredited  
SMi Pharma  
www.pain-therapeutics.co.uk  
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

Pain Therapeutics - Download Brochure

### 3. Biomarker Presentation from Collegium Pharmaceuticals

Where have we been and where should we go? Evaluating the role and development of Biomarkers.

Presented by Richard Malamaut, Chief Medical Officer & EVP at Collegium Pharmaceuticals

### 4. Novaremed's Deep Dive Session – Diabetic Neuropathic Pain

Exploring Novaremed's work in developing NRD.E1, an innovative therapy for diabetic neuropathic pain

Presented by Sara Mangialaio, Head of Research & Development and Chief Medical Officer at Novaremed

### 5. Virtual Conference: Online Access Only

Live and On Demand speaker content: Get access to the latest strategies and case studies from your marketplace online.

Network with all the event attendees: Connect, see who is attending, chat and share contact details with all online delegates, speakers and sponsors

Sponsors can Exhibit a Virtual Booth: pack a customized booth full of documents, videos and even show who is manning the booth during the event and hosting meetings

Host & Join Meetings & Socials: Join preferred speaking sessions, host meetings and even a virtual Networking social, with in built Zoom functionality

As Europe's leading pain therapeutics conference, which will analyse the latest developments in the field of pain drug development, this is a must-attend for those wanting to learn how the industry is working to overcome the challenges of opioid base treatment.

The full agenda, speaker line-up and brochure can be viewed online at: [www.pain-therapeutics.co.uk/pr2](http://www.pain-therapeutics.co.uk/pr2)

Sponsored by: Transpharmation and MD Biosciences

To join Pain Therapeutics Conference as a sponsor/exhibitor, please get in touch with Alia Malick, Director on +44 (0)20 7827 6168 or email [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or [ssapal@smi-online.co.uk](mailto:ssapal@smi-online.co.uk)

SMI's 21st Annual Pain Therapeutics Conference

10–11 May 2021

Virtual Conference: Online Access Only

<http://www.pain-therapeutics.co.uk/pr2>

#SMiPain

--- END---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Simi Sapal

SMi Group

+442078276000

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/535635672>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.